Aside from improving exercise capacity and quality of life in patients with chronic obstructive pulmonary disease (COPD), pulmonary rehabilitation also yields reductions in anxiety and depression symptoms, according to the results of a systematic review and meta-analysis.
Long-acting beta2-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) combinations compare with inhalers containing both LABA and corticosteroid (LABA-ICS) in terms of reducing chronic obstructive pulmonary disease (COPD) exacerbations, although the LAMA-LABA combination is more favourable as it is associated with fewer episodes of severe pneumonia, according to a study.
Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).
Digitalizing pulmonary rehabilitation using a smartphone app is feasible in the management of chronic obstructive pulmonary disease, with patients completing a 20-day core programme showing improvements in health-related quality of life, according to a study.
Combination therapy with inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) can be safely escalated to triple therapy in the management of patients with chronic obstructive pulmonary disease (COPD), a meta-analysis suggests. Specifically, adding a long-acting muscarinic receptor antagonist (LAMA) to the combination poses no major risk to increase cardiovascular serious adverse events.
Cognitive behavioural therapy (CBT) intervention delivered by respiratory nurses is effective in reducing anxiety symptoms and utilisation of healthcare resources in patients with chronic obstructive pulmonary disease (COPD), thus providing a cost-effective strategy for treating anxiety — a symptom often comorbid with COPD, according to a study.
Long-term consumption of fruits, but not vegetables, appears to be associated with a reduced risk of developing chronic obstructive pulmonary disease, according to data from the prospective Swedish Mammography Cohort study.
Adding targeted lung denervation to drug therapy more than halves the rate of adverse respiratory events compared with drug therapy alone in patients with persistent chronic obstructive pulmonary disease (COPD), according to the AIRFLOW*-2 trial presented at ERS 2018.
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.